NCT02221375已完成1 期
Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of Butylated Hydroxytoluene Via Respimat Soft MistTM Inhaler B (Sub-study 1) and Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of BI 54903 XX Via Respimat Soft MistTM Inhaler B as Randomised, Double-blind, Placebo-controlled Phase I Trial in Healthy Male Volunteers (Main Study) and Comparison of Systemic Exposure Following a Single Dose of BI 54903 XX Via Respimat Soft MistTM Inhaler B and of a Single Dose of Ciclesonide Via MDI (Randomised, Open-label, Two-way Crossover Sub-study 2)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 主要终点
- Number of patients with clinically significant findings in ECG
研究概览
简要总结
The objective of the study was to investigate safety, tolerability and pharmacokinetics of butylated hydroxytoluene (BHT) (sub-study 1) administered via Respimat® Soft MistTM Inhaler B (SMI B); to assess safety, tolerability and pharmacokinetics of multiple rising doses of BI 54903 XX administered via Respimat® SMI B (main study), and to compare systemic exposure of single dose BI 54903 XX administered via Respimat® SMI B (sub-study 2) with single dose Alvesco® (ciclesonide) administered via HFA-134a propellant metered dose inhaler (MDI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG) and clinical laboratory tests
- •Age >= 21 and <= 50 years
- •BMI >= 18.5 and <= 29.9 kg/m2
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (>24 h) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs that could reasonably influence the results of the trial within 10 days prior to administration or during the trial (based on the knowledge at the time of protocol preparation)
- •Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
- •Smoker (>10 cigarettes or >3 cigars or >3 pipes per day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g per day)
- •Drug abuse
- •Blood donation (>100 mL within 4 weeks prior to administration or during the trial)
- •Excessive physical activities (within 1 week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of the trial site
- •Bacterial and viral infections of the lung, including active or latent tuberculosis
研究组 & 干预措施
BHT low
Experimental
干预措施: BHT low (Drug)
BHT medium
Experimental
干预措施: BHT medium (Drug)
BHT high
Experimental
干预措施: BHT high (Drug)
BI 54903 XX low
Experimental
干预措施: BI 54903 XX low (Drug)
BI 54903 XX medium 1
Experimental
干预措施: BI 54903 XX medium 1 (Drug)
BI 54903 XX medium 2
Experimental
干预措施: BI 54903 XX medium 2 (Drug)
BI 54903 XX high
Experimental
干预措施: BI 54903 XX high (Drug)
BI 54903 XX medium single dose
Experimental
干预措施: BI 54903 XX medium 2 (Drug)
Ciclesonide
Active Comparator
干预措施: Ciclesonide (Drug)
结局指标
主要结局
Number of patients with clinically significant findings in ECG
时间窗: up to 21 days after last drug administration
Number of patients with adverse events
时间窗: up to 21 days after last drug administration
Number of patients with clinically significant findings in vitals signs
时间窗: up to 21 days after last drug administration
Number of patients with clinically significant findings in laboratory tests
时间窗: up to 21 days after last drug administration
Investigator assessed tolerability on a 4-point scale
时间窗: up to 21 days after last drug administration
Change in airway resistance (Raw)
时间窗: baseline, after 80 hours
次要结局
- tmax (time from dosing to maximum measured concentration in plasma)(up to 24 hours after last drug administration)
- AUC0-inf (area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity)(up to 24 hours after last drug administration)
- AUCt1-t2 (area under the concentration-time curve in plasma over the time interval from time t1 to time t2)(up to 24 hours after last drug administration)
- Cmax (maximum measured concentration in plasma)(up to 24 hours after last drug administration)
- AUCτ (area under the concentration-time curve in plasma over a uniform dosing interval τ)(up to 24 hours after last drug administration)
- AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the last quantifiable concentration at tz)(up to 24 hours after last drug administration)
- CLR,t1-t2 (renal clearance from the time point t1 until the time point t2)(up to 24 hours after last drug administration)
- %AUCtz-∞ (the percentage of the AUC 0-∞ that is obtained by extrapolation)(up to 24 hours after last drug administration)
- λz (terminal rate constant in plasma)(up to 24 hours after last drug administration)
- t1/2 (terminal half-life in plasma)(up to 24 hours after last drug administration)
- CL/F (apparent clearance in plasma following inhalation administration)(up to 24 hours after last drug administration)
- Accumulation ratio based on Cmax (RA,Cmax)(up to 24 hours after last drug administration)
- MRTih (mean residence time in the body after inhalation administration)(up to 24 hours after last drug administration)
- Metabolite-to-parent ratio for Cmax (RCmax,Met)(up to 24 hours after last drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following inhalation administration)(up to 24 hours after last drug administration)
- Aet1-t2 (amount that is eliminated in urine from the time point t1 to time point t2)(up to 24 hours after last drug administration)
- fet1-t2 (fraction that is eliminated in urine from time point t1 to time point t2)(up to 24 hours after last drug administration)
- Accumulation ratio based on AUC (RA,AUC)(up to 24 hours after last drug administration)
- Linearity index (LI)(up to 24 hours after last drug administration)
- Metabolite-to-parent ratio for AUC (AUCt1-t2,Met)(up to 24 hours after last drug administration)
研究者
相似试验
已完成
1 期
A Study to Test How Well Different Doses of BI 1584862 Are Tolerated by Healthy MenHealthyNCT06006598Boehringer Ingelheim50
终止
1 期
Single Rising Dose Study of BI 201335 ZW in Healthy Male SubjectsHealthyNCT02182271Boehringer Ingelheim8
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)HealthyNCT02337283Boehringer Ingelheim96
已完成
1 期
A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 765080HealthyNCT04666922Boehringer Ingelheim48
已完成
1 期
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles MidazolamHealthyNCT06327256Boehringer Ingelheim40